JP2011526609A - 避妊のための子宮内用送達システム - Google Patents

避妊のための子宮内用送達システム Download PDF

Info

Publication number
JP2011526609A
JP2011526609A JP2011515511A JP2011515511A JP2011526609A JP 2011526609 A JP2011526609 A JP 2011526609A JP 2011515511 A JP2011515511 A JP 2011515511A JP 2011515511 A JP2011515511 A JP 2011515511A JP 2011526609 A JP2011526609 A JP 2011526609A
Authority
JP
Japan
Prior art keywords
progestogen
delivery system
bleeding
core
therapeutically active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011515511A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011526609A5 (enExample
Inventor
ドゥエスターベルク，ベルント
アホラ，マンヤ
ピフラヤ，ユルキ
リューティカイネン，ヘイッキ
ユカライネン，ハッリ
クレーモラ，サトゥ
パルカッティ，テロ
Original Assignee
バイエル オイ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40020198&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2011526609(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by バイエル オイ filed Critical バイエル オイ
Publication of JP2011526609A publication Critical patent/JP2011526609A/ja
Publication of JP2011526609A5 publication Critical patent/JP2011526609A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0039—Devices retained in the uterus for a prolonged period, e.g. intrauterine devices for contraception
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Communication Control (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
JP2011515511A 2008-07-03 2009-07-01 避妊のための子宮内用送達システム Pending JP2011526609A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08397516A EP2140860A1 (en) 2008-07-03 2008-07-03 An improved method of contraception
EP08397516.9 2008-07-03
PCT/FI2009/050598 WO2010000943A1 (en) 2008-07-03 2009-07-01 An intrauterine delivery system for contraception

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014045808A Division JP6008893B2 (ja) 2008-07-03 2014-03-10 避妊のための子宮内用送達システム

Publications (2)

Publication Number Publication Date
JP2011526609A true JP2011526609A (ja) 2011-10-13
JP2011526609A5 JP2011526609A5 (enExample) 2012-07-19

Family

ID=40020198

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2011515511A Pending JP2011526609A (ja) 2008-07-03 2009-07-01 避妊のための子宮内用送達システム
JP2014045808A Active JP6008893B2 (ja) 2008-07-03 2014-03-10 避妊のための子宮内用送達システム
JP2016114446A Pending JP2016166245A (ja) 2008-07-03 2016-06-08 避妊のための子宮内用送達システム

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2014045808A Active JP6008893B2 (ja) 2008-07-03 2014-03-10 避妊のための子宮内用送達システム
JP2016114446A Pending JP2016166245A (ja) 2008-07-03 2016-06-08 避妊のための子宮内用送達システム

Country Status (23)

Country Link
US (3) US20110146693A1 (enExample)
EP (3) EP2140860A1 (enExample)
JP (3) JP2011526609A (enExample)
KR (2) KR20110026516A (enExample)
CN (2) CN103976816A (enExample)
AR (1) AR072544A1 (enExample)
CA (1) CA2730040A1 (enExample)
CL (1) CL2009001490A1 (enExample)
CY (1) CY1120878T1 (enExample)
DK (1) DK2905014T3 (enExample)
ES (1) ES2673154T3 (enExample)
HR (1) HRP20180869T1 (enExample)
HU (1) HUE037520T2 (enExample)
LT (1) LT2905014T (enExample)
PE (1) PE20100057A1 (enExample)
PL (1) PL2905014T3 (enExample)
PT (1) PT2905014T (enExample)
SI (1) SI2905014T1 (enExample)
SM (1) SMT201800295T1 (enExample)
TR (1) TR201807996T4 (enExample)
TW (2) TWI602556B (enExample)
UY (1) UY31957A (enExample)
WO (1) WO2010000943A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015514791A (ja) * 2012-04-23 2015-05-21 バイエル・ファルマ・アクチェンゲゼルシャフトＢａｙｅｒ Ｐｈａｒｍａ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ １８−メチル−１５β，１６β−メチレン−１９−ノル−２０−スピロキサ−４−エン−３−オンの子宮内使用、１８−メチル−１５β，１６β−メチレン−１９−ノル−２０−スピロキサ−４−エン−３−オンを含有する子宮内システム、ならびに避妊および婦人科学的処置におけるその使用
JP2016539088A (ja) * 2013-10-18 2016-12-15 バイエル・オサケユキテュアＢａｙｅｒ Ｏｙ 子宮内送達システム
JP2022521227A (ja) * 2019-02-22 2022-04-06 エルケム・シリコーンズ・ユーエスエイ・コーポレーション 有効成分の溶出を改善するための薬デリバリーシリコーン組成物

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2494706C2 (ru) 2008-09-17 2013-10-10 Байер Ой Устройство для введения
FI20080524A0 (fi) 2008-09-17 2008-09-17 Bayer Schering Pharma Oy Insertteri
FI20080523A0 (fi) 2008-09-17 2008-09-17 Bayer Schering Pharma Oy Insertteri
DE202012012713U1 (de) * 2011-03-04 2014-01-23 Arstat, Inc. Intravaginale Arzneimittelabgabevorrichtung
US10028858B2 (en) 2011-07-11 2018-07-24 Medicines360 Intrauterine systems, IUD insertion devices, and related methods and kits therefor
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
RS62297B1 (sr) 2011-11-23 2021-09-30 Therapeuticsmd Inc Prirodne kombinovane hormonske supstitucione formulacije i terapije
AR089765A1 (es) 2012-01-23 2014-09-17 Bayer Oy Un sistema para el suministro de un farmaco
USD718435S1 (en) 2012-05-30 2014-11-25 Medicines360 Intrauterine insertion device
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
SE539540C2 (sv) 2013-09-12 2017-10-10 Qpharma Ab Ett läkemedelsavgivningssystem för en eller flera aktiva beståndsdelar
JP2017516768A (ja) 2014-05-22 2017-06-22 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． 天然の併用ホルモン補充療法剤及び療法
WO2015189853A1 (en) 2014-06-13 2015-12-17 Meril Endo Surgery Private Limited An intrauterine device
TWI730948B (zh) * 2014-12-08 2021-06-21 芬蘭商拜耳股份有限公司 新穎的熱塑性聚胺甲酸酯，彼等材料於製造子宮內系統之ｔ-框架之用途及由此等材料製成之ｔ-框架
LT3247327T (lt) * 2015-01-21 2019-10-10 Bayer Oy Vaisto pateikimo sistema, apimanti nesteroidinį priešuždegiminį (nsaid) ir progestogeninį junginį, ir gamybos būdai
US20180140640A1 (en) 2015-04-22 2018-05-24 Cadens Beheer B.V. Improved contraceptive methods and compositions and devices for use therein
FI3294300T3 (fi) 2015-05-13 2025-03-06 Bayer Oy Pitkävaikutteinen lääkkeenantolaite implantin tai kierukan muodossa, joka käsittää levonorgestreelia ja etinyyliestradiolia
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
CN108430453B (zh) * 2015-12-21 2023-03-17 拜耳股份有限公司 制造药物递送装置的方法和根据该方法制成的药物递送装置
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
GB2555373A (en) * 2016-08-23 2018-05-02 Reproductive Medicine And Gynaecology Associates Ltd Implant
AU201617347S (en) * 2016-12-23 2017-01-23 Jurox Pty Ltd intravaginal device
AU2018340266A1 (en) * 2017-09-27 2020-03-05 Bayer Oy A method for modifying release of a therapeutically active agent from an elastomeric matrix
EP3727361A4 (en) 2017-12-22 2022-01-12 Alyra Biotech Pty Ltd TREATMENT OF PAIN AND/OR PAIN-RELATED SYMPTOMS RELATED TO DYSMENORRHEA
US20200268932A1 (en) * 2019-02-22 2020-08-27 Arsenal Aaa, Llc. Crosslinkable polymer compositions
KR102260999B1 (ko) * 2019-03-27 2021-06-04 (주)엠케어코리아 난소암 검사용 임플란트 및 이를 포함하는 검사킷 및 이를 이용한 난소암 검사방법
WO2020237325A1 (en) 2019-05-31 2020-12-03 Alyra Biotech Pty Ltd Methods, compositions and devices for treating neuroinflammatory conditions
CN110215447A (zh) * 2019-06-14 2019-09-10 上海市计划生育科学研究所 甲芬那酸在避孕药物中的应用及其制备的杀精避孕药物
WO2021102220A1 (en) 2019-11-21 2021-05-27 Coopersurgical, Inc. Packaging systems for implantable devices and related methods
CN116807727B (zh) * 2023-08-29 2023-11-21 上海宇度医学科技股份有限公司 一种妇产科医师用临床取环器
WO2025106820A1 (en) * 2023-11-16 2025-05-22 University Of South Florida Method of preventing progesterone contraceptive-induced abnormal uterine bleeding (aub)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01221318A (ja) * 1988-03-01 1989-09-04 Masao Igarashi ダナゾール含有の局所投与製剤
JPH10510168A (ja) * 1994-07-05 1998-10-06 レイラス オサケユイチア 活性剤の放出のためのデバイス
JP2000516585A (ja) * 1996-08-02 2000-12-12 ザ チルドレンズ メディカル センター コーポレイション 血管新生阻害物質による雌生殖系の調節方法
WO2002038159A1 (fr) * 2000-11-10 2002-05-16 Mitsubishi Pharma Corporation Medicaments pour l'hyperplasie endometriale
JP2003221338A (ja) * 2002-01-29 2003-08-05 Masao Igarashi 子宮腺筋症治療製剤
JP2005503389A (ja) * 2001-08-31 2005-02-03 シエーリング オサケユイチア 薬物送達システム
JP2007526903A (ja) * 2003-08-29 2007-09-20 アーダナ バイオサイエンス リミテッド 月経過多、月経困難症又は子宮内膜症の治療

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3880991A (en) * 1969-03-24 1975-04-29 Brook David E Polymeric article for dispensing drugs
US4188951A (en) 1972-08-17 1980-02-19 Alza Corporation Intrauterine system embracing selected copolymeric membranes for administering beneficial agent
US4495934A (en) 1978-07-25 1985-01-29 Shaw Jr Seth T IUD Arrangement
US4284074A (en) * 1978-07-26 1981-08-18 Shaw Jr Seth T IUD Arrangement
AU538963B2 (en) 1979-07-09 1984-09-06 Seth Thomas Shaw Jr. Drug for use with an iud
FR2539027B1 (fr) * 1983-01-07 1987-03-06 Levrier Marc Systeme endo-uterin contraceptif et therapeutique associant cuivre, argent, hormone naturelle et acide iso amino caproique
NL8603216A (nl) * 1986-12-17 1988-07-18 Kurz Karl Heinz Inrichting om in de uterus te plaatsen.
FR2695826B1 (fr) * 1992-09-21 1995-01-06 Theramex Nouvelles compositions pharmaceutiques à base de dérivés de nomégestrol et leurs procédés d'obtention.
FI94947C (fi) 1994-04-05 1995-11-27 Maillefer Nokia Holding Sovitelma lankamaisia tuotteita puolaavan koneen yhteydessä
FI97947C (fi) 1994-09-27 1997-03-25 Leiras Oy Menetelmä lääkepreparaatin valmistamiseksi
EP0944382A1 (en) 1996-09-30 1999-09-29 Brigham & Women's Hospital Methods and compounds for treatment of abnormal uterine bleeding
FI103051B (fi) 1997-08-22 1999-04-15 Schering Oy Uusia blokkikopolymeerejä ja niiden valmistus
FI107339B (fi) 1998-06-30 2001-07-13 Leiras Oy Lääkeaineiden läpäisynopeutta säätävä kalvo tai matriisi
US6056976A (en) 1998-11-12 2000-05-02 Leiras Oy Elastomer, its preparation and use
US20050033163A1 (en) 2001-04-24 2005-02-10 Impres Medical, Inc. Intrauterine implant and methods of use
DE10045380A1 (de) * 2000-09-14 2002-04-04 Schering Ag Verfahren zur Kontrazeption und dessen Darreichungsform
ATE461681T1 (de) * 2003-04-29 2010-04-15 Gen Hospital Corp Verfahren und vorrichtungen für die verzögerte freisetzung von mehreren arzneimitteln
FI123188B (fi) * 2005-04-05 2012-12-14 Bayer Oy Ultraäänellä havaittavissa oleva kohdunsisäinen järjestelmä
US7862552B2 (en) * 2005-05-09 2011-01-04 Boston Scientific Scimed, Inc. Medical devices for treating urological and uterine conditions
CN100441156C (zh) * 2006-09-30 2008-12-10 华中科技大学 一种复合材料宫内节育器

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01221318A (ja) * 1988-03-01 1989-09-04 Masao Igarashi ダナゾール含有の局所投与製剤
JPH10510168A (ja) * 1994-07-05 1998-10-06 レイラス オサケユイチア 活性剤の放出のためのデバイス
JP2000516585A (ja) * 1996-08-02 2000-12-12 ザ チルドレンズ メディカル センター コーポレイション 血管新生阻害物質による雌生殖系の調節方法
WO2002038159A1 (fr) * 2000-11-10 2002-05-16 Mitsubishi Pharma Corporation Medicaments pour l'hyperplasie endometriale
JP2005503389A (ja) * 2001-08-31 2005-02-03 シエーリング オサケユイチア 薬物送達システム
JP2003221338A (ja) * 2002-01-29 2003-08-05 Masao Igarashi 子宮腺筋症治療製剤
JP2007526903A (ja) * 2003-08-29 2007-09-20 アーダナ バイオサイエンス リミテッド 月経過多、月経困難症又は子宮内膜症の治療

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6013045936; Ｂｒｉｔｉｓｈ　Ｊｏｕｒｎａｌ　ｏｆ　Ｏｂｓｔｅｔｒｉｃｓ　ａｎｄ　Ｇｙｎａｅｃｏｌｏｇｙ Ｖｏｌ．１０８, 2001, ｐ．７４-８６ *
JPN6013045939; Ｄｒｕｇｓ Ｖｏｌ．６３，　Ｎｏ．１３, 2003, ｐ．１４１７-３３ *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015514791A (ja) * 2012-04-23 2015-05-21 バイエル・ファルマ・アクチェンゲゼルシャフトＢａｙｅｒ Ｐｈａｒｍａ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ １８−メチル−１５β，１６β−メチレン−１９−ノル−２０−スピロキサ−４−エン−３−オンの子宮内使用、１８−メチル−１５β，１６β−メチレン−１９−ノル−２０−スピロキサ−４−エン−３−オンを含有する子宮内システム、ならびに避妊および婦人科学的処置におけるその使用
JP2016539088A (ja) * 2013-10-18 2016-12-15 バイエル・オサケユキテュアＢａｙｅｒ Ｏｙ 子宮内送達システム
JP2022521227A (ja) * 2019-02-22 2022-04-06 エルケム・シリコーンズ・ユーエスエイ・コーポレーション 有効成分の溶出を改善するための薬デリバリーシリコーン組成物
JP7524203B2 (ja) 2019-02-22 2024-07-29 エルケム・シリコーンズ・ユーエスエイ・コーポレーション 有効成分の溶出を改善するための薬デリバリーシリコーン組成物

Also Published As

Publication number Publication date
EP2313084A1 (en) 2011-04-27
JP6008893B2 (ja) 2016-10-19
US20110146693A1 (en) 2011-06-23
LT2905014T (lt) 2018-07-10
PE20100057A1 (es) 2010-02-25
KR20110026516A (ko) 2011-03-15
US20180263899A1 (en) 2018-09-20
ES2673154T3 (es) 2018-06-20
US10532025B2 (en) 2020-01-14
CN103976816A (zh) 2014-08-13
EP2905014A1 (en) 2015-08-12
DK2905014T3 (en) 2018-06-25
CN102088954A (zh) 2011-06-08
UY31957A (es) 2010-01-29
EP2140860A1 (en) 2010-01-06
TWI602556B (zh) 2017-10-21
US20140127280A1 (en) 2014-05-08
JP2014129412A (ja) 2014-07-10
TW201601699A (zh) 2016-01-16
HUE037520T2 (hu) 2018-09-28
SI2905014T1 (en) 2018-08-31
JP2016166245A (ja) 2016-09-15
TR201807996T4 (tr) 2018-06-21
CA2730040A1 (en) 2010-01-07
EP2313084A4 (en) 2014-03-05
EP2905014B1 (en) 2018-04-25
CL2009001490A1 (es) 2010-08-06
WO2010000943A1 (en) 2010-01-07
CY1120878T1 (el) 2019-12-11
HRP20180869T1 (hr) 2018-08-24
US9999592B2 (en) 2018-06-19
KR101659530B1 (ko) 2016-09-23
TW201002288A (en) 2010-01-16
SMT201800295T1 (it) 2018-07-17
KR20150136143A (ko) 2015-12-04
AR072544A1 (es) 2010-09-08
PL2905014T3 (pl) 2018-10-31
PT2905014T (pt) 2018-06-22

Similar Documents

Publication Publication Date Title
JP6008893B2 (ja) 避妊のための子宮内用送達システム
ES2206865T3 (es) Dispositivo de suministro intravaginal de farmacos.
CN103002873B (zh) 用于治疗子宫内膜异位症的释放芳香化酶抑制剂和孕激素的肠外剂型
JP2014204989A (ja) 子宮内用システム
US20160262923A1 (en) Intrauterine delivery system
WO2010133757A1 (en) Vaginal delivery system
US20140005157A1 (en) Treatment of uterine fibroids by intravaginal administration of a low dose of selective progesterone receptor modulator (sprm), anti-progestin, or anti-progestational
US20170312219A1 (en) Method of contraception
ES2365552T3 (es) Sistema de administración vaginal.
US20200383906A1 (en) Hormonal contraception using a vaginal ring which releases estriol and trimegestone
HK1157208A (en) An intrauterine delivery system for contraception
HK1197641A (en) An intrauterine delivery system for contraception
US20150065472A1 (en) Intrauterine application of 18-methyl-15ss,16ss-methylene-19-nor-20-spirox-4-en-3-one systems, intrauterine systems containing 18-methyl-15ss,16ss-methylene-19-nor-20-spirox-4-en-3-one, as well as the use thereof in contraception and gynaecological therapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120604

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120604

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130912

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131011

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131021

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131129

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131206

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140627

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140627